Sulfamylon Related Published Studies
Well-designed clinical trials possibly related to Sulfamylon (Mafenide Topical)
A prospective double-blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: a pilot study. [2009.08]
A silver-coated antimicrobial barrier dressing used postoperatively on meshed autografts: a dressing comparison study. [2007.09]
Other research related to Sulfamylon (Mafenide Topical)
Systemic absorption of amphotericin B with topical 5% mafenide acetate/amphotericin B solution for grafted burn wounds: is it clinically relevant? [2010.02]
Allergic contact dermatitis to mafenide acetate: a case series and review of the literature. [2007.08]
Topical Sulfamylon cream inhibits DNA and protein synthesis in the skin donor site wound. [2006.05]
Mafenide acetate allergy presenting as recurrent chondritis. [2002.02]
Off-label drug use in WOC nursing: issues related to use of mafenide acetate to treat infected chronic wounds. [2001.09]
Topical mafenide hydrochloride aqueous spray in initial management of massive contaminated wounds with devitalized tissue. [2001.07]
Does the addition of nystatin to 5% mafenide acetate and genitourinary irrigant solutions interfere with their antimicrobial activity? Assessment by two topical antimicrobial test assay systems. [2001.07]
The use of 5% mafenide acetate solution in the postgraft treatment of necrotizing fasciitis. [2001.01]
Topical sulfamylon reduces engraftment of cultured skin substitutes on athymic mice. [1999.01]
Serious silver sulphadiazine and mafenide acetate dermatitis. [1995.06]
Five percent mafenide acetate solution in the treatment of thermal injuries. [1993.03]
Comparison of silver sulphadiazine 1 per cent, silver sulphadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent and mafenide acetate 8.5 per cent for topical antibacterial effect in infected full skin thickness rat burn wounds. [1991.02]
Use of 5% sulfamylon (mafenide) solution after excision and grafting of burns. [1988.11]
Mafenide-induced pseudochondritis. [1988.03]
Mafenide acetate concentrations and bacteriostasis in experimental burn wounds treated with a three-layered laminated mafenide-saline dressing. [1980.10]
Other possibly related research studies
Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective. [2004.04]
An in vivo comparison of topical agents on wound repair. [2001.09.01]
Efficacy of topical silver against fungal burn wound pathogens. [1999.08]
The use of a modified Dakin's solution (sodium hypochlorite) in the treatment of Vibrio vulnificus infection. [1999.03]
Beneficial effect of Aloe on wound healing in an excisional wound model. [1996.06]
In vitro susceptibility testing of topical antimicrobial agents used in pediatric burn patients: comparison of two methods. [1997.09]
Treatment of a severe alkali burn. [1996.03]
Comparison of the effects of commonly used wound agents on epithelialization and neovascularization. [1994.09]
Risk of aluminum accumulation in patients with burns and ways to reduce it. [1994.07]
Inhibition of wound contraction by topical antimicrobials. [1993.04]
Cytotoxicity to human leukocytes by topical antimicrobial agents used for burn care. [1993.03]
Review of the use of povidone-iodine (PVP-I) in the treatment of burns. [1993]
Burn of the auricle. [1992.05]
Effects of topical antimicrobial agents on the human neutrophil respiratory burst. [1991.05]
Preventing postoperative burn wound aspergillosis. [1991.03]
Fungal burn wound infection. A 10-year experience. [1991.01]
The efficacy of nystatin combined with topical microbial agents in the treatment of burn wound sepsis. [1989.11]
Comparison of standard and chlorhexidine-derivative topical antibacterial agents on the infected burned rat wound. [1988.04]
Comparison of battlefield-expedient topical antimicrobial agents for the prevention of burn wound sepsis in a rat model. [2005.07]
Topical treatment of pediatric patients with burns: a practical guide. [2002]
A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. [2000.03]
Current treatment recommendations for topical burn therapy. [1990.09]
Topical Bactroban (mupirocin): efficacy in treating burn wounds infected with methicillin-resistant staphylococci. [1990.09]
Analysis of infection in a burn ward. [1989.10]
A comparison of Biobrane vs. homograft for coverage of contaminated burn wounds. [1988.10]
Burn care standards in Israel: lack of consensus. [2005.11]
Managing extracavitary prosthetic vascular graft infections: a pathway to success. [2006.12]
[The antibacterial effect of cecropin B on pseudomonas aeruginosa infection of wounds in mice] [2006.12]
Seven years' experience with Integra as a reconstructive tool. [2007.01]
Management of bioburden with a burn gel that targets nociceptors. [2007.04]
A Silver-Coated Antimicrobial Barrier Dressing Used Postoperatively on Meshed Autografts: A Dressing Comparison Study. [2007.07.25]
Controlling methicillin resistant Staphyloccocus aureus and Pseudomonas aeruginosa wound infections with a novel biomaterial. [2007.07]
Comparison of therapeutic antibiotic treatments on tissue-engineered human skin substitutes. [2008.05]
Understanding and managing burn pain: Part 2. [2009.05]
Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? [2009.01]
Topical nanoemulsion therapy reduces bacterial wound infection and inflammation after burn injury. [2010.09]
Antibiotic-eluting bioresorbable composite fibers for wound healing applications: microstructure, drug delivery and mechanical properties. [2009.10]
Suprathel-antiseptic matrix: in vitro model for local antiseptic treatment? [2011.02]
The diversity of wound presentation associated with freon contact frostbite injury. [2010.09]
|